Degree in Biology from the Autonomous University of Barcelona and Master in management and leadership of science and innovation by the Barcelona School of Management-Pompeu Fabra. Mar has spent more than 15 years working on drug discovery and development projects. She has participated in the origin of companies such as Thrombotargets and Bionure as well as the Spanish National Centre for Genomic Analysis. At the moment she is Managing Director at Bionure, as well as leading the scientific development of projects in progress, mainly BN201 for the treatment of neurodegenerative diseases.
Former vice president at Novartis and former medical director at Genentech, responsible for clinical development in neuro-ophthalmology, developing and bringing to market the drug Rituximab for Multiple Sclerosis. He was principal investigator in the largest global trial of Optic Neuritis. He will become Chief Medical Officer at Bionure when Phase 2 clinical trials are to be started.
Co-founder. MD and PhD; Director of Neuroimmunology at University Hospital Clínic of Barcelona.
Medical doctor and PhD in neuroimmunology, Pablo discovered the Bionure drug after more than 15 years of research in neurology and in the field of Multiple Sclerosis. He has published more than 80 peer-reviewed articles and 8 patents related to new therapies and diagnostic methods for neurological diseases and retina. He is Director of Neuroimmunology at Hospital Clínic-IDIBAPS and Medical Director at Genentech-Roche.
Serial entrepreneur with more than 15 years in industry experience in business development and marketing in medical devices and pharmaceutical companies. Prior to founding Bionure, Albert was the Director of Technology Transfer at Hospital Clinic from the University of Barcelona. Albert has been involved in several start-ups mainly in life sciences: he is the founder and member of the Board at Spire Bioventures (accelerator for life sciences companies bridging Barcelona and Silicon Valley), strategic advisor at Psious and was the CEO at Linkcare (digital health), among others.